<dfn id="0gu2v"></dfn>
<dfn id="0gu2v"></dfn>
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Ayuso E, et al. Reference materials for the characterization of adeno-associated viral vectors. In: Cohen-haguenauer, O (ed). The Clinibook: clinical gene transfer state of the art. EDK: Paris: pp. 83-90, 2012.
Moullier P, Snyder RO. Recombinant adeno-associated viral vector reference standards. Methods Enzymol. 507: 297-311, 2012. PubMed: 22365780
Moullier P, Snyder, RO. International efforts for recombinant adeno-associated viral vector reference standards. Mol. Ther. 16:1185-1188, 2008.
Burger C. et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Molecular Therapy : 10(2):302-17, 2004 PubMed: 15294177
Tessier J, et al. Characterization of adenovirus-induced inverted terminal repeat-independent amplification of integrated adeno-associated virus rep-cap sequences. J. Virol. 75(1):375-383, 2001. PubMed: 11119606
Lock M, et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum. Gene Ther. 21(10): 1273-1285, 2010. PubMed: 20486768
Ayuso E, et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. 17(4): 503-510, 2010. PubMed: 19956269
<dfn id="x3rla"></dfn>